(Q37217972)

19 August 2017

1 reference

title

Current and future therapeutic approaches in progressive supranuclear palsy (English)

1 reference

19 August 2017

2

Irene Litvan

1 reference

19 August 2017

Irene van Balken

1

1 reference

19 August 2017

language of work or name

1 reference

1 January 2008

1 reference

Handbook of clinical neurology / edited by P.J. Vinken and G.W. Bruyn

19 August 2017

published in

1 reference

19 August 2017

volume

89

1 reference

19 August 2017

page(s)

493-508

1 reference

Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Mitochondrial dysfunction in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Evidence for oxidative stress in the subthalamic nucleus in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Frontal lobe dysfunction in progressive supranuclear palsy: evidence for oxidative stress and mitochondrial impairment

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

The `subcortical dementia' of progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Parallel Organization of Functionally Segregated Circuits Linking Basal Ganglia and Cortex

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: a positron emission tomographic study

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Dystonia in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Limited usefulness of electroconvulsive therapy in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Coenzyme Q10 as a possible treatment for neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Bioenergetic approaches for neuroprotection in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Gene therapy and cell transplantation for Alzheimer's disease and spinal cord injury

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Does the enhancement of cholinergic neurotransmission influence brain glucose kinetics and clinical symptomatology in progressive supranuclear palsy?

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Delayed administration may improve entacapone effects in parkinsonian patients non-responding to the drug.

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Tau protein isoforms, phosphorylation and role in neurodegenerative disorders11These authors contributed equally to this work

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

The fine structure of subcortical neurofibrillary tangles in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Serotonin receptors in cognitive behaviors

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Progressive supranuclear palsy in a sample of Brazilian population: clinical features of 16 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Propentofylline attenuates tau hyperphosphorylation in Alzheimer's Swedish mutant model Tg2576.

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Treatment of dystonic clenched fist with botulinum toxin

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

New therapeutic indications for botulinum toxins

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Frontal-subcortical circuits and human behavior

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Subcortical dementia. Frontal cortex hypometabolism detected by positron tomography in patients with progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

DA agonists -- ergot derivatives: lisuride: management of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Zolpidem in Progressive Supranuclear Palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Proton magnetic resonance spectroscopy in Steele-Richardson-Olszewski syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

L-dopa in progressive supranuclear palsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Natural history and clinical features of progressive supranuclear palsy: a clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

The Treatment of Progressive Supranuclear Palsy with L-Dopa

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Methysergide in progressive supranuclear palsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Treatment of progressive supranuclear palsy with amitriptyline: therapeutic and toxic effects

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Progressive supranuclear palsy presenting with dynamic aphasia

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Donepezil in the treatment of progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Proton magnetic resonance spectroscopy in Parkinson's disease and progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Proton magnetic resonance spectroscopy in Parkinson's disease and atypical parkinsonian disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct.

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Failure of cholinergic agonist RS-86 to improve cognition and movement in PSP despite effects on sleep.

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Effects of physostigmine on swallowing and oral motor functions in patients with progressive supranuclear palsy: A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Trophic factor distribution predicts functional recovery in parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Idazoxan treatment in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

The effect of botulinum toxin injections to the calf muscles on freezing of gait in parkinsonism: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Progression of gait, speech and swallowing deficits in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Frontal lobe function in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Progressive supranuclear palsy, computed tomography, and response to antiparkinsonian drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

The external globus pallidus in patients with Parkinson's disease and progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

The internal globus pallidus is affected in progressive supranuclear palsy and Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Initial experience with electroconvulsive therapy for progressive supranuclear palsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy).

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Pharmacologic Treatment of Emotional Lability

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Progressive supranuclear palsy: clinical features and response to treatment in 16 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Controlled trial of pergolide mesylate in Parkinson's disease and progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Pretarsal injection of botulinum toxin for blepharospasm and apraxia of eyelid opening

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

L-dopa for progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

The glamour and gloom of glycogen synthase kinase-3

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Tolcapone: a review of its use in the management of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Effects of Physostigmine on Spatial Attention in Patients With Progressive Supranuclear Palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

L-dopa for progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Autologous adrenal medullary transplant in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Pharmacological Therapy in Progressive Supranuclear Palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Nucleus-specific alteration of raphe neurons in human neurodegenerative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Patterns of abnormal motor cortex excitability in atypical parkinsonian syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Amitriptyline in the management of progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

[Sleep abnormalities and evoked potentials (VEP-BAER-SEP) in progressive supranuclear palsy]

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Treatment of progressive supranuclear palsy and corticobasal degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Are dopamine receptor agonists neuroprotective in Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Alterations of GABAergic neurons in the basal ganglia of patients with progressive supranuclear palsy: an in situ hybridization study of GAD67 messenger RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Neural stem cell therapy in the aging brain: pitfalls and possibilities

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Filamentous tau in oligodendrocytes and astrocytes of transgenic mice expressing the human tau isoform with the P301L mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Diagnosis and management of progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Physostigmine treatment of progressive supranuclear palsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Characterizing swallowing abnormalities in progressive supranuclear palsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Neuropsychiatric assessment of patients with hyperkinetic and hypokinetic movement disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Progressive supranuclear palsy: analysis of six cases

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

4-Hydroxynonenal, a product of lipid peroxidation, inhibits dephosphorylation of the microtubule-associated protein tau.

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Zolpidem in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Modification by L-dopa of a case of progressive supranuclear palsy. With evidence of defective cerebral dopamine metabolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Clinical and acoustical variability in hypokinetic dysarthria

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Progressive supranuclear palsy and normal-pressure hydrocephalus

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Aniracetam for treatment of patients with progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies.

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

The use of lisuride, a potent dopamine and serotonin agonist, in the treatment of progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Electroconvulsive therapy-responsive depression in a patient with progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Treatment of progressive supranuclear palsy with tricyclic antidepressants

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Retrospective study of drug response in 87 patients with progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Elementary motor perseveration in early diagnosis of progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Lipoperoxidation is selectively involved in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Management of referred deep brain stimulation failures: a retrospective analysis from 2 movement disorders centers

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Double-blind, placebo-controlled trials for surgical interventions in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR.

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Natural history of progressive supranuclear palsy: a clinicopathologic study from a population of brain donors

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Autoradiographic demonstration of loss of alpha 2-adrenoceptors in progressive supranuclear palsy: preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study.

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Progressive supranuclear palsy: pneumoencephalography, electronystagmography and treatment with methysergide

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Ocular Manifestations in Progressive Supranuclear Palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Bilateral deep brain stimulation of the pedunculopontine nucleus for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Progressive supranuclear palsy: functional analysis of the response to methysergide and antiparkinsonian agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Rotigotine: in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

L-dopa for progressive suparanulcear palsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Transcranial AC pulsed applications of weak electromagnetic fields reduces freezing and falling in progressive supranuclear palsy: a case report.

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

AAV2-mediated gene delivery to monkey putamen: evaluation of an infusion device and delivery parameters

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Progressive supranuclear palsy with agitation: response to trazodone but not to thiothixine or carbamazepine

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Botulinum toxin a in the treatment of blepharospasm: a 10-year experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

The course of cervical dystonia and patient satisfaction with long-term botulinum toxin A treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

PROGRESSIVE SUPRANUCLEAR PALSY. A HETEROGENEOUS DEGENERATION INVOLVING THE BRAIN STEM, BASAL GANGLIA AND CEREBELLUM WITH VERTICAL GAZE AND PSEUDOBULBAR PALSY, NUCHAL DYSTONIA AND DEMENTIA.

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Neuroreplacement therapy and stem cell biology under disease conditions.

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

NORTRIPTYLINE FOR THE TREATMENT OF DEPRESSION IN PROGRESSIVE SUPRANUCLEAR PALSY

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Autopsy-proven progressive supranuclear palsy in two siblings

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

L-dopa for progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Caregiving in progressive supranuclear palsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Current and future treatments in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Pramipexole in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Reductions in acetylcholine and nicotine binding in several degenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Result of long-term administration of L-threo-3,4-dihydroxyphenylserine in patients with pure akinesia as an early symptom of progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Pure akinesia manifested neuroleptic malignant syndrome: a clinical variant of progressive supranuclear palsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Progressive supranuclear palsy: postmortem chemical analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

DA agonists -- ergot derivatives: pergolide: management of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

Naloxone in progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0072-9752%2807%2901246-8

7 January 2021

10.1016/S0072-9752(07)01246-8

Identifiers

DOI

1 reference

19 August 2017

1 reference